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Intravenous vortioxetine to accelerate onset of effect in major 
depressive disorder: a 2-week, randomized, double-blind, 
placebo-controlled study
Eduard Vietaa, Ioana Floreab, Simon Nitschky Schmidtb, Johan Arebergb  
and Anders Ettrupb 
This 2-week randomized, double-blind, placebo-controlled 
fixed-dose study (NCT02919501) explored the potential of 
accelerating onset of antidepressant efficacy and plasma 
exposure with single-dose intravenous vortioxetine at 
oral vortioxetine treatment initiation. Outpatients (ages 
18–65 years) with major depressive disorder and a current 
depressive episode (Montgomery Åsberg Depression 
Rating Scale total score ≥30) were randomized to an 
initial single dose of either intravenous vortioxetine 
17 mg (n = 27) or intravenous placebo (n = 28), both 
treatments followed by 2 weeks of oral vortioxetine (10 
mg/day). From baseline to day 7, both groups exhibited 
fast and substantial improvements by approximately 14 
Montgomery Åsberg Depression Rating Scale points, with 
no statistically significant treatment difference for this 
primary endpoint. Improvements were substantial already 
within 24 hours, with numerical treatment differences 
of 1.3 and 1.6 points at days 1 and 3, respectively, in 
favour of intravenous vortioxetine + oral vortioxetine. 
Pharmacokinetic data confirmed that intravenous 
vortioxetine facilitated reaching steady-state plasma 
concentration within 24 hours. Intravenous vortioxetine 
+ oral vortioxetine was safe and well-tolerated, with 
nausea as the most common adverse event. This study 
supported intravenous vortioxetine as a means of rapidly 
reaching therapeutic vortioxetine blood levels. Int Clin 
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Introduction
Major depressive disorder (MDD) is a disabling illness 
with significant negative impact on patients’ daily 
functioning and quality of life (American Psychiatric 
Association, 2016). In spite of a wide range of pharmaco-
therapeutic options, most currently available antidepres-
sants require some weeks to induce clinically relevant 
symptomatic improvement (Machado-Vieira et al., 2008). 
Lagged onset of therapeutic effect may have negative 
implications for short- and long-term clinical outcomes, 
for example by compromising adherence and timely 
changing of treatment, as well as increasing the risk of 
suicide (Machado-Vieira et al., 2008; Witkin et al., 2018). 
Antidepressant treatments that provide immediate symp-
tomatic relief may therefore help reduce the overall bur-
den of disease, for the individual patient, and in a global 
public health perspective (World Health Organization, 
2017). This unmet need in the treatment of depression 
is reflected in the current focus in drug development on 
potentially fast-acting antidepressant compounds, mainly 
targeting glutamatergic pathways, and with a few in late-
stage development (Witkin et al., 2018; Daly et al., 2018).







receptor antagonist, a 5-HT
1B
 receptor partial agonist, 
a 5-HT
1A
 receptor agonist, and an inhibitor of the ser-
otonin transporter (SERT) that has demonstrated 
robust antidepressant efficacy and a favourable tolera-
bility profile broadly across patient populations (Katona 
et al., 2012; Thase et al., 2016; Baldwin et al., 2016b). 
Pre-clinical studies indicate that vortioxetine may have 
potential to accelerate the onset of effect, theoretically 
by its 5-HT
1A
 receptor agonism, which may lead to rapid 
desensitizing of autoreceptors in the raphe nucleus 
(Bétry et al., 2013). In addition, its 5-HT
3
 receptor antag-
onism may reduce GABAergic input from hippocampal 
interneurons, which may in turn increase serotonin-me-
diated activation of glutamatergic neurons in the frontal 
cortex (Artigas et al., 2018). Thereby, vortioxetine may 
counteract the initial suppression of 5-HT neurotrans-
mission following inhibition of the SERT thought to 
account for the 2–3 weeks’ lag of effect seen with selec-
tive serotonin reuptake inhibitors (SSRIs) (Bétry et al., 
2013; Artigas et al., 2018).
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Despite the potential for faster antidepressant onset of 
action suggested by pre-clinical data, there is no doc-
umentation of such effects in available clinical study 
data. However, vortioxetine has a relatively long half-
life, on average 66 hours, with steady-state plasma con-
centration levels reached after approximately 2 weeks, 
which may delay the onset of beneficial pharmacological 
effects (Areberg et al., 2014). Moreover, approved dos-
ages of vortioxetine for the treatment of MDD comprise 
5–20 mg/day administered perorally, with recommended 
starting doses of 5–10  mg/day. Consequently, plasma 
exposure of vortioxetine is low on the first day after 
dosing. Methods to attain steady-state levels faster and 
increase initial exposure may potentially provide faster 
symptomatic relief. Intravenous (IV) administration 
of the drug directly into systemic circulation, thereby 
bypassing first-pass metabolism, may be one method to 
increase initial plasma exposure. Vortioxetine has previ-
ously been administered intravenously to healthy sub-
jects (Areberg et al., 2012).
The aim of this study was to explore the early efficacy, 
the pharmacokinetics (PK), and the safety and tolerabil-
ity, of a single initial, IV dose of vortioxetine added to 
daily oral vortioxetine, with the purpose of reducing the 
time to onset of antidepressant effect from 2–3 weeks to 
7 days or less.
Methods
Study design and patients
In this multi-site, parallel-group, fixed-dose study, 
patients were randomized 1:1 to double-blind treat-
ment with either a single dose of IV vortioxetine 17 mg 
(0.068 mg/ml solution infused over 2 hours) plus 2 weeks 
of open-label oral vortioxetine 10  mg/day (IV vortioxe-
tine + oral vortioxetine), or a single dose of IV saline infu-
sion plus 2 weeks of open-label oral vortioxetine 10 mg/
day (IV placebo + oral vortioxetine).
The study included outpatients aged 18–65 years 
with recurrent MDD (per DSM-5), who experienced 
a current major depressive episode (classification 
code 296.3x). Patients had to be severely depressed, 
with a Montgomery Åsberg Depression Rating Scale 
(MADRS) total score ≥30 at screening and at baseline, 
and with the current depressive episode lasting at 
least 3 months. Patients with any psychiatric comor-
bidity, including alcohol or other substance abuse/
dependence, a history of mania, hypomania, or any 
psychotic disorder, were excluded, as were patients 
who were pregnant, at risk of suicide, or who had any 
impairments likely to compromise the validity of the 
assessments. Patients with a current depressive epi-
sode resistant to two antidepressants treatments at 
recommended doses and of at least 6 weeks’ duration, 
were excluded to avoid including patients with treat-
ment-resistant depression.
Patients were hospitalized for observation for 24 hours 
after the IV infusion, after which period they continued 
the study as outpatients. A safety follow-up was con-
ducted approximately 4 weeks after the end of treat-
ment. Two blinded safety and tolerability evaluations 
were conducted internally after randomization of 8 and 
20 patients, before continuing the study.
The dose of 17  mg vortioxetine to be administered 
intravenously was determined based on PK simulations 
showing that the steady-state plasma drug level reached 
after 2–3 weeks of treatment with a conventional dose 





ues of 14 ng/ml and 326 ng*h/ml, respectively [Areberg 
et al., 2014]), would be obtained within 24 hours with the 
combined doses of 17  mg IV and 10  mg oral vortioxe-
tine. A standard 10 mg/day oral dose of vortioxetine was 
used as comparison, adding placebo (IV saline) to ensure 
blinding against IV vortioxetine. All patients received 
first oral dose immediately before the infusion.
The study was conducted between September 2016 and 
April 2017 at seven sites in Estonia and Finland. Study 
protocols and amendments were approved by the inde-
pendent ethics committee of each trial site. The trial 
was conducted in accordance with the International 
Conference on Harmonization Good Clinical Practices 
guidelines and with the ethical principles of the 
Declaration of Helsinki. The trial is registered at 
ClinicalTrials.gov (NCT02919501).
Assessments
Efficacy and safety data were collected at day 0 (base-
line), and at days 1, 3, 7 and 14 post-baseline; adverse 
events in addition at 2 hours (i.e., immediately after the 
IV infusion). Blood samples for vortioxetine assessments 
were collected on day 1 (three samples; 2, 8 and 24 hours 
post-IV infusion) and day 14 (one sample; no specific 
sampling time specified).
The primary efficacy measure was the MADRS 
(Montgomery and Asberg, 1979), a 10-item clinician-re-
ported rating scale assessing depressive symptom severity. 
In this study, the MADRS was modified to assess symp-
toms within the time since previous visit, i.e., for the past 
1, 2 or 4 days at days 1, 3 and 7, respectively. MADRS total 
score (possible score range 0–60) was calculated as the 
sum of scores on single items. A six-item subscale score 
of the MADRS (MADRS-6) was calculated as the sum of 
the following items: Apparent sadness, reported sadness, 
inner tension, lassitude, inability to feel and pessimistic 
thoughts (item numbers 1, 2, 3, 7, 8 and 9). The MADRS-6 
subscale was developed to provide a more unidimensional 
representation of the core symptoms of depression com-
pared with the full scale and has demonstrated higher sen-
sitivity to detect treatment differences (Bech et al., 2002; 
Bech, 2006; Thase et al., 2012). For the MADRS scales, 
higher scores indicate worse symptom severity.
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Disease severity and improvement were recorded by cli-
nicians using the Clinical Global Impressions-Severity 
of Illness (CGI-S) and CGI-Improvement (CGI-I) (Guy, 
1976). Both scales range from 1 to 7, with higher CGI 
scores indicating worse status/worsening of illness, a 
CGI-I score of four reflecting neither improvement nor 
worsening relative to baseline.
The Hospital Anxiety and Depression Scale (HADS) was 
used to assess patient-rated symptoms of depression 
(HADS-D) and anxiety (HADS-A) (Zigmond and Snaith, 
1983). Total score for each of the seven-items subscales 
was calculated as the sum of scores on single items (pos-
sible score range 0–21), higher scores indicating higher 
symptom severity.
Safety and tolerability assessments included reported 
adverse events, vital signs, clinical safety laboratory 
tests, electrocardiograms (ECGs) and physical exam-
inations. Suicidality was rated and monitored using 
the Columbia-Suicide Severity Rating Scale (Posner 
et al., 2011).
Statistical analyses
Safety analyses comprised all randomized patients who 
received IV infusion or took at least one tablet (treated 
patients), with treatment-emergent adverse events 
(TEAEs) summarized using descriptive statistics. 
Efficacy analyses comprised all patients who received 
infusion and took at least one tablet, and who had a 
valid MADRS total score assessment at baseline and at 
least one valid MADRS assessment before or at day 7 
post-baseline (the full-analysis set).
The primary efficacy endpoint assessing the change from 
baseline at day 7 in MADRS total score was analysed using 
a restricted maximum likelihood-based mixed model for 
repeated measurements (MMRM), including study site, 
day and treatment as factors, baseline MADRS total score 
as a covariate, and interactions for treatment-by-day and 
baseline MADRS total score-by-day. The mean difference 
between treatment groups at day 7 was estimated based 
on the least squares mean for the treatment-by-day inter-
action in the MMRM-model.
Key secondary endpoints, the changes from baseline in 
MADRS total score at days 14, 3 and 1, respectively, were 
analysed using the same approach. Mean changes from 
baseline and mean treatment differences with standard 
errors are reported, unless otherwise stated.
To account for multiplicity, the primary and key secondary 
endpoints were tested according to the following, hierar-
chically ordered sequence:
(1) change from baseline to day 7 in MADRS total score 
(primary endpoint);
(2) change from baseline to day 14 in MADRS total score;
(3) change from baseline to day 3 in MADRS total score;
(4) change from baseline to day 1 in MADRS total score.
If an endpoint in the sequence did not reach statistical 
significance at an alpha level of 5%, the testing strategy 
was stopped, and subsequent P-values were considered 
nominal.
Other endpoints were analysed using MMRM models 
similar to that specified for the primary endpoint, with 
CGI-S baseline score included as a covariate in the anal-
yses of outcomes for CGI-I and the change from baseline 
in MADRS-6 subscale score analysed post hoc.
All statistical tests are two-sided. Data were analysed 
using SAS, Version 9.4 statistical software.
Sample size determination
Assuming an effect size at day 7 of 4.7 points in MADRS 
total score with an SD of 6.0, a total of 54 patients (27 per 
treatment arm) would provide a power of approximately 
80% at an alpha level of 5%.
Based on pre-clinical data supporting the potential for fast 
onset (Bétry et al., 2013; Sanchez et al., 2015), a steady-
state exposure level obtained at day 1 with the IV 17 mg 
dose was hypothesized to result in an effect size at day 
7 that would correspond to the effect size seen after 2–3 
weeks with 10 mg oral vortioxetine. The assumed effect 
size of 4.7 MADRS points at day 7 was based on the theo-
retical change from baseline with the conventional 10 mg 
oral dose of vortioxetine (approximately 5 points) versus 
week 3 (approximately 10 points).
Population pharmacokinetic analysis
The sampled plasma concentrations of vortioxetine were 
analysed using non-linear mixed effect methods, based on 
a previously developed model for vortioxetine (Areberg 
et al., 2014). The population PK model was used to sim-
ulate full individual plasma concentration-time profiles 
and estimate area under the curve and C
max
 parameters 
for days 0, 3, 7 and 14.
Results
Of 55 patients randomized, 54 (98.2%) completed the 
study (Fig.  1). The mean age of the total sample was 
approximately 45 years, and most patients were women 
(74.1% and 82.1% in the IV vortioxetine and IV placebo 
group, respectively; Table 1). The mean MADRS total 
score at baseline was approximately 34. No notable dif-
ferences between the treatment groups in demographic 
characteristics or baseline clinical assessments were 
seen, except for a substantially higher mean duration of 
the current depressive episode for the IV placebo + oral 
vortioxetine group (54.0 versus 25.3 weeks). This differ-
ence was driven by two patients in the IV placebo group 
(cf. Table 1). The median duration of the current depres-
sive episode was approximately 22 weeks in both treat-
ment groups.
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Efficacy
From baseline to day 7, patients in both treatment groups 
showed considerable improvements, with a reduction of 
approximately 14 points in MADRS total score, and no 
statistically significant treatment difference (Fig. 2). The 
primary endpoint was therefore not met, and subsequent 
P-values were considered nominal, in accordance with 
the testing strategy.
Across the 2-week study period, mean MADRS total 
score steadily decreased in both treatment groups. The 
improvement was most pronounced within the first 3 
days, with a MADRS total score change from baseline at 
day 1 of −7.2 points for IV vortioxetine + oral vortioxe-
tine and −5.9 points for IV placebo + oral vortioxetine, 
and with numerical treatment differences of 1.3 and 1.6 
in favour of IV vortioxetine at days 1 and 3, respectively. 
Similarly, MADRS-6 subscale score, and CGI-S and 
CGI-I scores decreased in both treatment groups across 
the study period; overall, these numerical improvements 
were more pronounced in the IV vortioxetine group.
Similar patterns were seen for other endpoints assessing 
patient-reported symptoms of depression and anxiety 
as measured by HADS-D and HADS-A, respectively; 
in particular, patients in both treatment groups reported 
substantial reduction in anxiety levels throughout the 
study. Patients treated with IV vortioxetine reported 
numerically larger improvement in anxiety up to day 7, 
with the changes from baseline for the treatment groups 
converging at day 14.
Pharmacokinetics
The concentration of vortioxetine in plasma, as reflected 
in C
max
, of 12 ng/ml at day 0 among patients receiving IV 
vortioxetine, were close to the expected steady-state lev-
els of 14 ng/ml predicted by a simulation model (Fig. 3). 
C
max
 was on average 4.3, 1.4 and 1.1 times higher at days 
0, 3 and 7, respectively, for IV vortioxetine + oral vorti-
oxetine versus IV placebo + oral vortioxetine, and con-
verged at day 14.
Safety
During the treatment period, 78% (n  =  21) of patients 
treated with IV vortioxetine + oral vortioxetine and 64% 
(n = 18) of those treated with IV placebo + oral vortioxe-
tine reported TEAEs. TEAEs were predominantly mild 
or moderate, with a total of two patients, both in the IV 
vortioxetine group, reporting severe TEAEs (anxiety and 
fatigue, respectively; Table 2)
The most common TEAE in both treatment groups was 
nausea, reported by 48% (n = 13) of patients in the IV vor-
tioxetine group and 32% (n = 9) in the IV placebo group. 
All events of nausea were mild or moderate (moderate-in-
tensity nausea reported by one patient in the IV placebo 
group and two in the IV vortioxetine group), with com-
parable severity levels between the groups. No patients 
Fig. 1
Patient disposition. *Lost to follow-up.
Table 1 Demographic and baseline clinical characteristics
IV vortioxetine + oral 
vortioxetine (n = 27)
IV placebo + oral 
vortioxetine 
(n = 28)
Demographic and clinical 
characteristics
  
 Women, n (%) 20 (74.1) 23 (82.1)
 Age (years) 46.0 (15.0) 43.8 (13.2)
 Caucasian, n (%) 27 (100) 28 (100)
 BMI (kg/m2) 27.1 (5.1) 29.1 (6.6)
 Mean duration of current 
depressive episode (weeks)a
25.3 (11.7) 54.0 (94.6)
 Median duration (weeks) 21.0 22.5
 Number of previous depressive 
episodes
2.9 (2.0) 2.8 (1.8)
Clinical assessments   
 Depressive symptoms   
  MADRS total score 34.6 (3.2) 33.4 (2.2)
 Clinical status   
  CGI-S score 5.3 (0.5) 5.2 (0.7)
 Patient-reported symptoms   
  HADS depression subscale 12.8 (3.2) 11.8 (3.6)
  HADS anxiety subscale 11.9 (4.0) 11.1 (3.0)
Mean (SD) reported unless otherwise specified.
Demographic and clinical characteristics based on all treated patients; clinical 
assessments based on the full-analysis set.
MADRS, Montgomery Åsberg Depression Scale; CGI-I, Clinical Global 
Impressions-Improvement; CGI-S, Clinical Global Impressions-Severity Of 
Illness; HADS-A, Hospital Anxiety and Depression Scale-Anxiety.
aTwo patients in the IV placebo + oral vortioxetine group reported mean durations 
of 286 and 460 weeks, respectively.
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
IV vortioxetine in MDD Vieta et al. 157
reported vomiting. Among patients treated with IV vorti-
oxetine who experienced nausea, most (nine of 13) TEAEs 
of nausea began within 24 hours after the IV dose, with no 
new incidences after day 2, and a mean duration of 4.5 
days. Among patients treated with IV placebo, events of 
nausea began relatively later (mean onset approximately 
2 days) and were of longer duration (mean = 12.5 days).
One patient in the IV placebo group reported treat-
ment-emergent sexual dysfunction (erectile dysfunc-
tion) while no patients reported insomnia or sedation. 
No deaths or serious adverse events occurred during the 
study, and none of the patients withdrew because of an 
adverse event. There were no notable findings in the clin-
ical safety laboratory tests, vital signs or ECG parameters.
Fig. 2
Efficacy assessments across study period (FAS, MMRM). IV vortioxetine + oral vortioxetine, n = 27; IV placebo + oral vortioxetine, n = 28. 
Treatment differences are based on the least squares means; error bars represent standard errors. CGI-I, Clinical Global Impressions-
Improvement; CGI-S, Clinical Global Impressions-Severity of Illness; FAS, full-analysis set; HADS-A, Hospital Anxiety and Depression Scale-
Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; IV, intravenous; MADRS, Montgomery Åsberg Depression Scale; MMRM, 
mixed model for repeated measurements.
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Discussion
In this study, all patients showed immediate and substan-
tial symptomatic improvement in MADRS total score, 
with no statistically significant treatment difference at 
day 7. Hence, the primary endpoint was not met, and 
P-values are considered nominal. At days 1 and 3, numer-
ically larger improvements were seen with IV vortioxe-
tine versus IV placebo. Similar patterns were seen across 
outcomes on MADRS-6, CGI and HADS scales.
PK results showed that an initial, single-dose infusion 
of vortioxetine accelerated attainment of steady-state 
concentrations, as the C
max
 values highly approximated 
the prediction of plasma exposure level of vortioxetine 
reached within 24 hours to correspond to steady-state 
levels for 10  mg/day oral dosing reached after approxi-
mately 14 days. The early clinical response seen in the 
IV vortioxetine group was consistent with exposure 
levels. Also, based on PK, the symptomatic response in 
the groups would be predicted to converge at day 14, as 
observed for the majority of endpoints.
Historically, IV formulations to accelerate onset of ther-
apeutic action have been investigated for a number 
of existing antidepressants, including the TCA clomi-
pramine and the SSRI citalopram, with mixed results 
(Guelfi et al., 2000; Moukaddam and Hirschfeld, 2004; 
Norman and Olver, 2004). The success of compounds 
currently in development in consistently achieving fast 
onset of action is yet to be seen (Freedman et al., 2018). 
These studies typically used repeated IV administrations 
whereas this study administered a single initial IV dose 
followed by oral dosing. Considering that the antidepres-
sant effect of vortioxetine has been demonstrated at lower 
Fig. 3
Simulated and estimated plasma concentration. IV vortioxetine + oral vortioxetine, n = 27; IV placebo + oral vortioxetine, n = 28. C
max
, maximum 
concentrations; IV, intravenous; PopPK, population pharmacokinetics.
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SERT occupancy compared with SSRIs (Stenkrona et al., 
2013; Sanchez et al., 2015), and the rapid desensitizing 





 receptor antagonism (Bétry et al., 2013), 
the mode of action of vortioxetine may plausibly carry a 
potential for fast therapeutic action.
The symptomatic improvement among patients who 
received IV placebo + oral vortioxetine was both larger 
and earlier than anticipated, although it should be noted 
that the existing knowledge on very early efficacy (<5 
days) with fast-acting antidepressants is limited. Still, in 
previous short-term studies with oral vortioxetine 10 mg/
day, the mean changes from baseline at 1 week after first 
dose were in the order of five MADRS points or less 
(Alvarez et al., 2012, Katona et al., 2012). Although changes 
from baseline to day 7 of approximately five and 10 points 
were expected a priori for IV placebo + oral vortioxetine 
and IV vortioxetine + oral vortioxetine, respectively, both 
treatment groups improved by 14 points from baseline 
to day 7. Various factors may have contributed to this 
finding: first, the hospitalization procedure of the study 
prioritized safety precautions against the risk of effects 
arising from the hospital care and environment; second, 
the IV procedure was likely to augment the perceived 
potency–and thus expectancy-driven placebo-response–
of the treatment, due to a more invasive procedure rela-
tive to oral treatment; likewise, patients’ expectations of 
an early effect would be likely to produce early-onset pla-
cebo-response. Finally, the repeated assessments at short 
intervals could increase the placebo response, as might 
the absence of a placebo-only treatment arm, implying 
certainty of receiving an active treatment (Schedlowski 
et al., 2015; Carlino and Vase, 2018).
Across assessments, the numerical treatment differences 
were largest up to day 3 and converged from day 7. At the 
time of study, the optimal endpoint time for vortioxetine 
as an IV formulation was not known but the results sug-
gest that initial boosting with IV vortioxetine may poten-
tially translate into a therapeutic effect already within 24 
hours after administration, and that day 7 may therefore 
be too late to capture the effect. However, the numerical 
treatment differences that were seen at day 7 for depres-
sive symptoms, as measured by the MADRS-6 subscale 
and the patient-rated HADS-D, indicate that assessment 
method–in particular the sensitivity of the rating scale–
may also play a role. Further, the similarity in results for 
the MADRS-6 subscale to those for MADRS total score 
support this briefer scale as sufficient to capture treat-
ment changes in core depressive symptoms.
Vortioxetine as oral and IV formulations showed over-
all good safety and tolerability profiles. The differential 
patterns of TEAEs of nausea in the respective treatment 
groups appeared to reflect vortioxetine exposure, with 
indications of earlier onset and shorter duration of nau-
sea with IV vortioxetine compared to IV placebo; how-
ever, it should be kept in mind that these descriptions 
were based on a small number of patients reporting nau-
sea (n = 22). Overall, TEAEs of nausea observed in this 
study align with general results for the program, showing 
that vortioxetine-induced nausea is transient (Baldwin 
et al., 2016a; Vieta et al., 2017). Moreover, the indication 
of exposure-dependent onset and duration might support 
nausea following IV vortioxetine as centrally mediated, 
since peripheral mediation via the gastro-intestinal sys-
tem would require longer time to onset. This is consist-
ent with the mechanism of action and tolerability profile 
already described for the oral formulation (Salagre et al., 
2018; Baldwin et al., 2016a).
Study limitations included the small sample size, and the 
absence of a placebo-only arm, for which reason it was not 
possible to quantify the response attributable to IV pla-
cebo alone. Finally, although PK results were as expected, 
the optimal therapeutic dose for this new formulation of 
vortioxetine was not well defined, and it might be con-
sidered if the IV dose of 17 mg used in this study was too 
low. Still, the findings from this study may inform future 
studies, which are warranted to further investigate the 
potential of vortioxetine to induce fast antidepressant 
relief, using other routes than per oral administration 
while aiming at minimizing placebo effects.
Conclusion
In this study, a single, initial dose of IV vortioxetine 17 mg 
added to oral vortioxetine 10 mg/day was not superior to 
IV placebo plus oral vortioxetine 10 mg/day in improv-
ing depressive symptoms as measured by MADRS total 
score at day 7. Substantial symptomatic improvements 
in both treatment groups were seen already within 24 
hours after the IV doses, with numerical treatment differ-
ences at days 1 and 3 in favour of vortioxetine. PK data 
Table 2 Summary of treatment emergent adverse events, and 
treatment emergent adverse events with an incidence of ≥5% in 
either treatment group in the 2-week treatment period
IV vortioxetine + oral 
vortioxetine
IV placebo + oral 
vortioxetine
Treated patients, n 27 28
Patients with TEAEs, n (%) 21 (77.8) 18 (64.3)
TEAEs occurring in ≥5% in either 
treatment group, n (%)
  
 Nausea 13 (48.1) 9 (32.1)
 Headache 4 (14.8) 4 (14.3)
 Anxiety 3 (11.1) 1 (3.6)
 diarrhoea 3 (11.1) 1 (3.6)
 Fatigue 2 (7.4) 4 (14.3)
 Somnolence 2 (7.4) 1 (3.6)
 Tachycardia 2 (7.4) 1 (3.6)
 Nasopharyngitis 1 (3.7) 4 (14.3)
 Erectile dysfunction 0 1 (20.0a)
 Hyperhidrosis 0 2 (7.1)
No serious adverse events or deaths occurred during the study. No patients with-
drew due to adverse events.
IV, intravenous; TEAE, treatment emergent adverse event.
aOf men in this treatment group (n = 5).
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confirmed IV vortioxetine to result in steady-state blood 
concentration levels within 24 hours. Vortioxetine as oral 
and IV formulations was well-tolerated, with nausea as 
the most common TEAE.
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